We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+11.44%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
-$4.88M
Cap. Flow
-$2.83M
Cap. Flow %
-6.15%
Top 10 Hldgs %
52.4%
Holding
53
New
2
Increased
15
Reduced
16
Closed
3
Avg Time Held Equity + Options
2.1 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
2.1 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
1.2 years

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.14M
2
LITS icon
Lite Strategy Inc
LITS
+$1.23M
3
EXEL icon
Exelixis
EXEL
+$280K
4
INCY icon
Incyte
INCY
+$71.3K
5
ALKS icon
Alkermes
ALKS
+$55.5K

Top Sells

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.11M
2
NKTR icon
Nektar Therapeutics
NKTR
+$1.15M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$671K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$382K
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$281K

Sector Composition

Rank Sector Weight
1 Healthcare 71.92%
2 Miscellaneous 28.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AKBA icon
26
Akebia Therapeutics
AKBA
$193M
$499K 1.08%
50,004
– –
2017 Q1
5 quarters
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$1.5B
$485K 1.05%
6,311
-980
-13% -$63.3K
2016 Q1
9 quarters
AXSM icon
28
Axsome Therapeutics
AXSM
$8.47B
$427K 0.93%
133,500
– –
2017 Q1
5 quarters
NKTR icon
29
Nektar Therapeutics
NKTR
$1.29B
$417K 0.9%
569
-993
-64% -$1.15M
2014 Q4
14 quarters
PCRX icon
30
Pacira BioSciences
PCRX
$1.45B
$401K 0.87%
12,500
– –
2016 Q3
7 quarters
ADMS
31
DELISTED
Adamas Pharmaceuticals
ADMS
$387K 0.84%
15,000
– –
2015 Q4
10 quarters
CKPT icon
32
DELISTED
Checkpoint Therapeutics
CKPT
$336K 0.73%
11,276
– –
2017 Q2
4 quarters
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$335K 0.73%
3,998
-498
-11% -$36.5K
2016 Q3
7 quarters
CRL icon
34
Charles River Laboratories
CRL
$14.6B
$307K 0.67%
2,734
+121
+5% +$13.1K
2016 Q4
6 quarters
GILD icon
35
Gilead Sciences
GILD
$195B
$301K 0.65%
4,251
+584
+16% +$41.2K
2016 Q4
6 quarters
NBIX icon
36
Neurocrine Biosciences
NBIX
$13.9B
$301K 0.65%
3,065
-167
-5% -$14.9K
2016 Q3
7 quarters
UTHR icon
37
United Therapeutics
UTHR
$23.2B
$301K 0.65%
2,660
+81
+3% +$8.9K
2017 Q3
3 quarters
EXEL icon
38
Exelixis
EXEL
$15.6B
$292K 0.63%
+13,555
New +$280K
2018 Q2
0 quarters
TECH icon
39
Bio-Techne
TECH
$11.4B
$282K 0.61%
7,628
-408
-5% -$15.6K
2016 Q4
6 quarters
IQV icon
40
IQVIA
IQV
$44.6B
$278K 0.6%
2,789
-100
-3% -$9.99K
2016 Q2
8 quarters
GRFS icon
41
Grifois
GRFS
$5.13B
$268K 0.58%
12,442
-980
-7% -$21.4K
2016 Q2
8 quarters
MDCO
42
DELISTED
Medicines Co
MDCO
$257K 0.56%
7,000
– –
2015 Q4
10 quarters
BLUE icon
43
DELISTED
bluebird bio
BLUE
$256K 0.56%
126
+24
+24% +$54.7K
2018 Q1
1 quarter
PGEN icon
44
Precigen
PGEN
$2.58B
$245K 0.53%
17,580
-898
-5% -$15.2K
2016 Q4
6 quarters
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$3.4B
$234K 0.51%
15,328
-21,405
-58% -$382K
2017 Q3
3 quarters
PRTK
46
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$204K 0.44%
20,000
– –
2015 Q4
10 quarters
CFRX
47
DELISTED
ContraFect Corporation
CFRX
$166K 0.36%
94
– –
2016 Q3
7 quarters
PGNX
48
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$88K 0.19%
10,891
– –
2017 Q1
5 quarters
SCTL
49
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$63K 0.14%
14,066
– –
2016 Q4
6 quarters
SCYX icon
50
SCYNEXIS
SCYX
$38.9M
$55K 0.12%
416
– –
2017 Q1
5 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opus Point Partners Management held 53 positions worth $46.1M, down 9.6% from $51M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opus Point Partners Management withdrew a net $2.83M in Q2 2018, closing 3 positions and reducing 16 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $671K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 65% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Lite Strategy Inc worth $1.58M.

  • Opus Point Partners Management's largest Q2 2018 buy was Lite Strategy Inc: 20,000 shares worth $1.58M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q2 2018, an estimated $3.14M increase.
  • Opus Point Partners Management's biggest Q2 2018 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $5.11M.
  • Opus Point Partners Management fully exited Karyopharm Therapeutics in Q2 2018, selling an estimated $671K.
  • Opus Point Partners Management's ten largest holdings make up 52% of its $46.1M portfolio in Q2 2018.
  • Opus Point Partners Management opened 2 new positions and closed 3 in Q2 2018.
  • Opus Point Partners Management's portfolio value fell 9.6% quarter-over-quarter to $46.1M.

Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.